Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02841709 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder
A Phase 2 study, sponsored by Idorsia Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT02841709 is a Phase 2 study that has completed, run by Idorsia Pharmaceuticals. The registered enrollment target is 58 participants.
The verdict
NCT02841709, a Phase 2 study, has completed, sponsored by Idorsia Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
This study evaluates the dose response of ACT-541468 on the change of wake after sleep onset (WASO) assessed by polysomnography (PSG) on the first 2 days of each treatment period.
Interventions
- DRUG Placebo
- DRUG ACT-541468
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2016-11-28 |
| Est. Completion | 2017-06-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02841709
The ClinicalTrials.gov registry entry for NCT02841709 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Idorsia Pharmaceuticals, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02841709 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02841709 about?
NCT02841709 is a clinical study titled "Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder". This study evaluates the dose response of ACT-541468 on the change of wake after sleep onset (WASO) assessed by polysomnography (PSG) on the first 2 days of each treatment period.
What is the current status of trial NCT02841709?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2016-11-28. Estimated completion is 2017-06-29.
What interventions are being tested in trial NCT02841709?
The interventions under investigation include: Placebo (DRUG), ACT-541468 (DRUG).
Who is sponsoring clinical trial NCT02841709?
This trial is sponsored by Idorsia Pharmaceuticals, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.